CBER Submissions Tracking, Top-Down Review Rank With Device Reforms
This article was originally published in The Gray Sheet
Executive Summary
CBER administrative reform of its document control center (DCC) will include hiring five more FTEs and coordinating submissions processing across center branches
You may also be interested in...
FDA Biologics Center Seeking To Address Device Industry Concerns – Zoon
Responsibility for the regulation of products related to blood safety should remain with FDA's Center for Biologics Evaluation & Research, according to CBER Director Kathryn Zoon
FDA Biologics Center Seeking To Address Device Industry Concerns – Zoon
Responsibility for the regulation of products related to blood safety should remain with FDA's Center for Biologics Evaluation & Research, according to CBER Director Kathryn Zoon
AdvaMed 2002 Annual Meeting In Brief
Meet Mark Kramer: Former CDRH staff college director becomes FDA's point-of-contact for combination products Feb. 25. Working within the FDA ombudsman's office, Kramer will canvass opinions from internal and external stakeholders, advocate more complex reviews of combination products, and navigate firms' requests for designation. At the AdvaMed 2002 Annual Meeting in Carlsbad, California, Center for Biologics Evaluation & Research Deputy Director Jesse Goodman outlined Kramer's role - to "deal with specific problems, interact with manufacturers, and sort of do a better job of bringing all of us to the table to update intercenter agreements." In addition, Kramer will help develop standard operating procedures for intercenter collaboration and consultation. As the first in a series of public meetings devoted to jurisdictional issues, FDA anticipates hosting a May public meeting on tissue-engineered devices. Kramer's background includes experience working in the device industry and CDRH's Office of Device Evaluation...